NF2 and neoplasm: Inhibitors of the TEAD transcription factors have shown effectiveness in inhibiting the growth of YAP/TAZ activated tumor cells (e.g., Nf2-mutated mesothelioma cells) and are currently being tested in cancer clinical trials.